GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (DUB:OVXA) » Definitions » EV-to-EBIT

Ovoca Bio (DUB:OVXA) EV-to-EBIT : 1.69 (As of May. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Ovoca Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ovoca Bio's Enterprise Value is €-3.85 Mil. Ovoca Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-2.28 Mil. Therefore, Ovoca Bio's EV-to-EBIT for today is 1.69.

The historical rank and industry rank for Ovoca Bio's EV-to-EBIT or its related term are showing as below:

DUB:OVXA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.12   Med: 0   Max: 1.74
Current: 1.69

During the past 13 years, the highest EV-to-EBIT of Ovoca Bio was 1.74. The lowest was -1.12. And the median was 0.00.

DUB:OVXA's EV-to-EBIT is ranked better than
62.5% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs DUB:OVXA: 1.69

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ovoca Bio's Enterprise Value for the quarter that ended in Jun. 2023 was €3.73 Mil. Ovoca Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-2.28 Mil. Ovoca Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -61.29%.


Ovoca Bio EV-to-EBIT Historical Data

The historical data trend for Ovoca Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio EV-to-EBIT Chart

Ovoca Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.98 -1.03 1.30 -1.08 -0.21

Ovoca Bio Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.08 - -0.21 -

Competitive Comparison of Ovoca Bio's EV-to-EBIT

For the Biotechnology subindustry, Ovoca Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovoca Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's EV-to-EBIT falls into.



Ovoca Bio EV-to-EBIT Calculation

Ovoca Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-3.849/-2.283
=1.69

Ovoca Bio's current Enterprise Value is €-3.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ovoca Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovoca Bio  (DUB:OVXA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ovoca Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-2.283/3.725104
=-61.29 %

Ovoca Bio's Enterprise Value for the quarter that ended in Jun. 2023 was €3.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ovoca Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovoca Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovoca Bio (DUB:OVXA) Business Description

Traded in Other Exchanges
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio (DUB:OVXA) Headlines

No Headlines